Conditions: Carcinoma, Non-Small-Cell Lung
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
To determine the appropriateness of the dose of nintedanib 200 mg b.i.d. plus docetaxel 75 mg/m2 as starting dose by evaluating the safety in Japanese patients with body surface area (BSA) \<1.5 m2 and locally advanced or metastatic adenocarcinoma subtype non-small cell lung cancer (NSCLC) after failure of first line platinum- based chemotherapy

Detailed description:

Arms:
arm 1: patients to receive backbone chemotherapy and nintedanib

Interventions: intervention 1: Nintedanib intervention 2: Docetaxel
Intervention descriptions: intervention 1: Nintedanib intervention 2: Docetaxel

Protocol document: